Capricor Therapeutics a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced the expansion of its strategic plan to further develop the company’s exosome platform technologies. In conjunction with these efforts, Stephen Gould, Ph.D. has been appointed as Executive Consultant to guide Capricor’s development of exosome-based vaccines and exosome-based therapeutics. Dr. Gould, a Professor of Biological Chemistry at Johns Hopkins University, is an internationally recognized exosome expert who brings an unparalleled understanding of exosome engineering to Capricor’s exosome-based research and development programs.
“One of the reasons the exosomes are potentially so useful and transformative is their ability to speak the language of a cell. We are excited by the commitment of Dr. Gould to help us explore the potential of exosome-based vaccines to help prevent human diseases and exosome-based therapeutics in treating human diseases. We look forward to announcing more updates shortly which will further outline some of our near-term goals within our exosomes program,” said Linda Marbán, Ph.D., Capricor’s president and chief executive officer.
Dr. Gould stated, “Exosomes are the body’s natural way of sending complex signals between cells and tissues. As a result, exosome-based vaccines have the potential to elicit more effective immune reactions against infectious agents and cancers, while exosome-based therapeutics have the potential to stabilize drugs and deliver them to their intended site of action. In addition, Capricor’s extensive expertise in cell culture and exosome purification provide it with numerous advantages for the scale-up and processing of exosome-based products, and together we will work to apply that ability to the production of viral vaccines, vesicle-mediated protein therapies, and treatment of inherited diseases. It’s a pleasure to be working with the talented Capricor team as we work together to develop exosome-based vaccines and drugs.”
Capricor has presented strong preclinical data using its proprietary cardiosphere-derived cell (CDC)-exosomes in many animal models. More specifically, Capricor has utilized this technology in pre-clinical studies of inflammation and intense immune activation such as DMD, sepsis, Graft- versus-host disease (GVHD) and trauma. While Capricor’s CDC-derived exosomes have strong clinical potential, Capricor is committed to developing precision-engineered exosomes that carry defined sets of effector molecules which exert their effects through defined mechanisms of action.
Source – Capricor